Table 2.
Clinical characteristics, treatment and BMD at each time point for those with available DXA data
| Clinical characteristics | Women | Men | ||||||
| Inclusion | 2 years | 5 years | 10 years | Inclusion | 2 years | 5 years | 10 years | |
| Number | 157 | 138 | 122 | 89 | 63 | 58 | 51 | 33 |
| Age (years) mean (SD) | 58.5 (15.6) | 60.8 (15.7) | 64.1 (15.2) | 66.9 (14.4) | 63.2 (11.1) | 64.9 (11.3) | 66.5 (11.2) | 69.3 (11.5) |
| BMI (kg/m2) mean (SD) | 24.9 (3.9) | 25.6 (4.3) | NA | NA | 25.3 (3.6) | 25.8 (4.1) | NA | NA |
| CRP (mg/L) median (IQR) | <9.0 (<9.0; 22.0) | <9.0 (<9.0; 10.0) | <9.0 (<9.0; 9.0) | <9.0 (<9.0; 9.0) | 13.0 (<9.0; 33.0) | <9.0 (<9.0; 15.0) | <9.0 (<9.0; 12.0) | <9.0 (<9.0; 23.0) |
| ESR (mm) median (IQR) | 21.0 (10.0; 43.0) | 15.0 (8.0; 24.0) | 15.0 (9.0; 24.0) | 15.5 (11.0; 26.0) | 22.0 (10.0; 46.0) | 15.5 (9.0; 30.5) | 16.0 (9.0; 25.3) | 18.5 (10.3; 31.8) |
| Erosions n (%) | 21 (13.4) | 37 (28.5) | 41 (35.7) | 25 (37.3) | 11 (17.5) | 28 (49.1) | 27 (57.4) | 16 (69.6) |
| HAQ median (IQR) | 0.75 (0.38; 1.25) | 0.63 (0.13; 1.06) | 0.75 (0.38; 1.25) | 0.75 (0.38; 1.19) | 0.63 (0.13; 1.13) | 0.32 (0.00; 0.91) | 0.25 (0.00; 0.88) | 0.57 (0.13; 1.00) |
| DAS28 mean (SD) | 4.63 (1.37) | 3.75 (1.39) | 3.69 (1.41) | 3.24 (0.96) | 4.57 (1.48) | 3.39 (1.40) | 3.25 (1.31) | 3.01 (1.09) |
| VAS global (mm) mean (SD) | 43.3 (27.1) | 36.6 (27.3) | 36.2 (25.2) | 31.6 (23.4) | 43.3 (26.1) | 26.6 (21.9) | 29.9 (23.7) | 28.9 (25.7) |
| VAS pain (mm) mean (SD) | 40.3 (25.6) | 35.2 (28.3) | 32.4 (24.5) | 29.9 (23.3) | 42.9 (28.7) | 24.8 (20.3) | 25.1 (21.8) | 26.4 (21.6) |
| sDMARDs n (%) | 128 (81.5) | 110 (82.7) | 93 (76.9) | 57 (70.4) | 54 (85.7) | 48 (82.8) | 41 (80.4) | 26 (81.3) |
| bDMARDs n (%) | 0 (0) | 9 (6.5) | 21 (17.2) | 21 (23.6) | 0 (0) | 4 (6.9) | 8 (15.7) | 7 (21.2) |
| Corticosteroids n (%) | 57 (36.3) | 44 (33.1) | 38 (31.4) | 20 (22.5) | 31 (49.2) | 15 (25.9) | 12 (23.5) | 8 (25.0) |
| Corticosteroids dose (mg/d) mean (SD) | 8.0 (4.3) | 5.2 (2.2) | 5.0 (2.7) | 6.4 (8.1) | 11.1 (6.3) | 5.3 (3.3) | 5.8 (5.0) | 6.6 (3.0) |
| Calcium and D-vitamin n (%) | 50 (33.1) | 87 (66.9) | 74 (69.2) | 34 (51.5) | 16 (26.7) | 29 (55.8) | 21 (58.3) | 14 (66.7) |
| Bisphosphonates n (%) | 5 (3.3) | 33 (25.4) | 38 (35.5) | 17 (25.8) | 0 (0) | 9 (17.3) | 6 (16.7) | 7 (33.3) |
| HRT n (%) | 24 (15.8) | 20 (15.4) | 15 (14.1) | 0 (0) | NA | NA | NA | NA |
| BMD femoral neck (g/cm2) mean (SD) | 0.85 (0.17) | 0.83 (0.17) | 0.82 (0.18) | 0.82 (0.15) | 0.88 (0.16) | 0.87 (0.14) | 0.86 (0.15) | 0.86 (0.13) |
| BMD lumbar spine (g/cm2) mean (SD) | 1.07 (0.20) | 1.08 (0.19) | 1.10 (0.20) | 1.14 (0.18) | 1.16 (0.20) | 1.16 (0.20) | 1.15 (0.20) | 1.18 (0.22) |
| Z-score femoral neck mean (SD) | −0.04 (1.03) | −0.09 (0.98) | −0.07 (1.11) | 0.11 (0.92) | −0.27 (1.10) | −0.37 (0.99) | −0.38 (1.09) | −0.30 (0.91) |
| Z-score lumbar spine mean (SD) | −0.02 (1.04) | 0.06 (0.99) | 0.26 (1.05) | 0.58 (0.99) | −0.12 (1.06) | −0.07 (1.07) | −0.15 (1.02) | −0.01 (1.13) |
bDMARDs, biological disease-modifying antirheumatic drugs; BMD, bone mineral density (g/cm2); BMI, body mass index; CRP, C reactive protein; DAS28, Disease Activity Score-28 Joints; DXA, dual-energy X-ray absorptiometry; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HRT, hormone replacement therapy; NA, not available/not applicable; sDMARDs, synthetic disease-modifying antirheumatic drugs; VAS, Visual Analogue Scale.